In Primary Breast Cancer, Letrozole and Cyclophosphamide Plus Sorafenib Show Activity
the Cancer Therapy Advisor take:
According to a new small study published in the British Journal of Cancer, researchers have found that the combination of letrozole, metronomic cyclophosphamide, and sorafenib shows activity and is well tolerated for the treatment of patients with primary breast cancer.
For the study, researchers enrolled 13 postmenopausal patients with estrogen receptor-positive, T2-4, N0-1 primary breast cancer. All patients received the three-drug regimen for 6 months.
Results showed that adequate plasma concentrations of sorafenib were achieved when participants received all three drugs at the same time, but average plasma concentrations of cyclophosphamide were decreased after receiving the three drugs versus when receiving letrozole and cyclophosphamide only.
The most frequent serious adverse events were diarrhea, hand-foot skin reaction, and skin rash. Of the 13 patients, six achieved a clinical complete response per RECIST Criteria, and all patients experienced a significant decrease in tumor size (P=0.005). In addition, at 30 days, 8 of 10 evaluable patients demonstrated a response and 11 of 13 evaluable patients demonstrated a response at the time of definitive surgery.
There was also a significant reduction in certain biomarkers, such as Ki67, CD31, and VEGF-A, following treatment with letrozole, cyclophosphamide, and sorafenib.
Combination of letrozole, metronomic cyclophosphamide, and sorafenib shows activity.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Plastics and Cancer
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Larotrectinib Continues to Show Efficacy in TRK-Fusion Cancers
- First-Line Nivolumab Alone or With Ipilimumab Continues to Show Durable Survival Benefits in Advanced Melanoma
- Talazoparib Improves PROs in BRCA-Positive Triple-Negative Breast Cancer
- Entrectinib Shrank NTRK Fusion-Positive Solid Tumors
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer